Company to webcast in­­vestor event, Sunday, De­cem­ber 6 at 8:30 p.m. ET

Orlando, FL (Press Release) – bluebird bio, Inc. (NASDAQ:BLUE), a clin­i­cal-stage com­pany com­mit­ted to devel­op­ing poten­tially trans­for­ma­tive gene ther­a­pies for severe ge­netic dis­eases and T cell-based im­mun­o­therapies for cancer, an­nounced that pre-clinical data from its anti-BCMA on­col­ogy pro­gram were pre­sented by bluebird bio scientists at the 57th American Society of He­ma­tol­ogy Annual Meeting.

“We be­lieve the unique science and trans­la­tional gene ther­apy plat­forms we have built dif­fer­en­ti­ate bluebird bio in the on­col­ogy field and have the poten­tial to yield im­por­tant new ther­a­pies for patients living with can­cer. Our three on­col­ogy posters at …